Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Biotech
GSK doubles down on Chimagen with $750M multiple myeloma wager
GSK is betting the trispecific can improve on the "difficult tolerability profiles" of existing T-cell engagers.
Nick Paul Taylor
Sep 15, 2026 7:15am
BMS’ pivotal CAR-T multiple myeloma trial hits primary endpoint
Sep 8, 2026 9:11am
AbbVie bispecific shows promise in ph. 3 multiple myeloma trial
Sep 3, 2026 9:20am
ASCO: Lilly's faith in Kelonia rewarded with ‘nutty’ CAR-T data
May 31, 2026 8:00am
ASCO: BMS CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3
May 29, 2026 8:00am
CellCentric raises $220M to advance myeloma drug
May 6, 2026 7:00am
